Patent Foramen Ovale (PFO) Closure Devices Market Analysis & Forecast: 2026-2033
The Patent Foramen Ovale (PFO) Closure Devices Market is anticipated to grow at a CAGR of 7.6% with USD 1.6 Bn share in 2026 and is expected to reach USD 2.6 Bn in 2033. The Patent Foramen Ovale (PFO) Closure Devices market is driven by the high global prevalence of PFO, present in an estimated 20‑30% of adults and strongly linked with cryptogenic stroke and embolic events, prompting preventative interventions in patients under 60 with unexplained stroke. Minimally invasive device use such as Amplatzer and Gore occluders has grown as regulatory approvals have strengthened clinical adoption, though off‑label use persists. Clinical evidence from journals like MDPI confirms high procedural success (~99%) and low complication rates, while bibliometric analysis highlights expanding research and guideline endorsements, with many data points published in 2024–2025.
(Source: MDPI; NCBI; Frontiersin.org)
Amplatzer PFO Occluder is projected to account for the largest share of cognitive systems spending in 2026, representing approximately 58.0% of the total volume. The Amplatzer PFO Occluder segment dominates the Patent Foramen Ovale (PFO) closure devices market due to its long-established clinical track record, high procedural success, and extensive adoption across hospitals worldwide. Key factors include over 95% technical success rates, robust long-term outcomes demonstrated in trials such as RESPECT and CLOSE, low complication rates, and FDA/CE regulatory approvals. Its repositionable, recapturable design and compatibility with various PFO anatomies make it the preferred choice among interventional cardiologists. In 2025–2026, Abbott reported that Amplatzer PFO Occluder accounted for the majority of PFO closure procedures in high-volume U.S. and European centers, reinforcing its dominance. Additionally, strong physician familiarity, widespread training programs, and extensive post-market evidence enhance confidence in device selection, supporting hospital adoption and maintaining leadership over competing occluder devices.
(Source: Abbott; FDA; JACC; Structural Heart Society)
To learn more about this report, Request Free Sample
Based on end users, hospitals dominate the market, accounting for a significant 72.0% share in 2026, because they provide the comprehensive infrastructure and specialized clinical teams required for these complex procedures. PFO closure typically requires advanced cath labs, high-resolution imaging, structural heart specialists, and on-site emergency support, which are predominantly available in hospital settings. In 2025–2026, over 90% of PFO closure procedures were performed in hospital cath labs, with high-volume centers (>200 structural heart procedures annually) reporting lower complication rates and >95% procedural success. Hospitals also serve as referral centers for cryptogenic stroke patients, integrating cardiology and neurology expertise, which increases procedural volume and ensures optimal patient outcomes. This combination of specialized infrastructure, experienced teams, procedural volume, and established patient pathways makes hospitals the primary and dominant segment for PFO closure device deployment globally.
(Sources: SCAI; Journal of Interventional Cardiology; Structural Heart Society)
The rising incidence of cryptogenic stroke is a major driver of the Patent Foramen Ovale (PFO) closure devices market, as these strokes—strokes with no identifiable cause—are increasingly linked to PFO presence in adults. Studies indicate that approximately 25% of adults have a PFO, and nearly one-third of ischemic strokes are cryptogenic, creating a substantial target population for intervention. In 2025–2026, hospitals in the U.S. and Europe reported that over 60% of PFO closures were performed following cryptogenic stroke events, highlighting the growing clinical focus on secondary stroke prevention. Early detection and multidisciplinary evaluation by neurologists and cardiologists enable timely identification of patients eligible for transcatheter closure, improving outcomes. Clinical trials, such as the RESPECT and DEFENSE-PFO studies, have reinforced the benefits of closure in reducing recurrent stroke risk, increasing physician confidence. This trend is further supported by guideline updates recommending closure for select patients aged 18–60 years with high-risk PFO anatomy, driving procedural adoption globally.
(Source: Mayo Clinic; SCAI; JACC 2025–2026)
The growing body of clinical evidence supporting PFO closure is a critical factor driving the market expansion of the Patent Foramen Ovale (PFO) closure devices market. Recent landmark trials, including RESPECT, DEFENSE-PFO, and CLOSE, have demonstrated that transcatheter PFO closure significantly reduces the risk of recurrent ischemic stroke in patients with cryptogenic stroke compared to medical therapy alone. In 2025–2026, follow-up data from these trials reported a nearly 50% reduction in recurrent stroke events among patients receiving PFO closure, with high procedural success rates exceeding 95% and low complication incidences. These robust clinical outcomes have increased physician confidence, encouraging neurologists and cardiologists to recommend closure for appropriately selected patients. Additionally, guideline updates from the Society for Cardiovascular Angiography & Interventions (SCAI) and European Society of Cardiology (ESC) now incorporate PFO closure as a standard secondary prevention option for high-risk patients aged 18–60 years. This growing clinical validation has accelerated hospital adoption, expanded patient referral pathways, and reinforced market demand globally.
|
Current Event |
Description and its Impact |
|
Regulatory approvals continue to support PFO closure adoption |
|
|
EU medical device regulation is increasing compliance and traceability requirements |
|
|
Government-funded stroke programs are improving diagnosis and referral pathways |
|
|
NIH-supported stroke research is strengthening evidence-based treatment decisions |
|
|
Public health reimbursement and clinical commissioning policies are defining access |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
North America account 45.0% market share in 2026, due to its large stroke-treatment pool, strong interventional cardiology infrastructure, favorable clinical guidelines, and rapid regulatory adoption. In the U.S., stroke remains a major clinical burden, with the CDC reporting over 795,000 strokes annually, including 610,000 first/new strokes, and 87% being ischemic strokes; this creates a sizeable referral base for PFO evaluation after cryptogenic stroke. PFO is present in about one-quarter of adults, and closure is clinically relevant when PFO is linked to unexplained embolic stroke. In January 2026, the AHA/NIH 2026 Statistics Update reinforced stroke as a major monitored cardiovascular condition, supporting continued clinical focus. In April 2026, the American Academy of Neurology reaffirmed its PFO secondary stroke prevention advisory, noting meaningful benefit for selected younger patients. FDA-cleared devices also support adoption; Abbott’s Amplatzer PFO Occluder is indicated for patients mainly aged 18–60 years with cryptogenic stroke.
(Source: CDC; escardio.org, professional.heart.org, aan.com, FDA.gov)
The Asia-Pacific region is poised to be as the fastest-growing region through 2026-2033, owing to due to rising stroke burden, improving cardiac-care infrastructure, and growing adoption of minimally invasive stroke-prevention procedures. In January 2026, the Asian Development Bank Institute reported that Asia and the Pacific account for more than half of the global stroke burden, creating a large clinical need for advanced secondary stroke-prevention solutions. PFO closure demand is further supported by clinical evidence showing that PFO is present in nearly 25% of the general adult population and may reach up to 50% among cryptogenic stroke patients, as reported in a May 2025 peer-reviewed review. Asia-Pacific experts also highlighted in the Journal of Stroke, 2025 that PFO closure reduces recurrent stroke/TIA risk versus medical therapy in selected patients. Wider use of contrast echocardiography, transcranial Doppler screening, urban cardiac centers, and device-based interventions in China, Japan, India, South Korea, and Southeast Asia is strengthening regional procedure adoption.
The U.S. patent foramen ovale (PFO) closure devices market dominates North America given its lead due to its high clinical burden of ischemic stroke and strong evidence‑driven adoption of closure therapy, as documented in peer‑reviewed journals and public domain sources. In the U.S., over 750,000 individuals suffer stroke annually, with 87% being ischemic, and roughly 25–40% of cryptogenic ischemic strokes occur in patients aged ≤60, where PFO is implicated; this substantial clinical need underpins procedural demand. Major randomized trials in the U.S. demonstrating that PFO closure significantly reduces recurrent ischemic stroke compared with medical therapy have strengthened clinician confidence and informed guideline updates, as highlighted in a July 28, 2025 JAMA review. Crucially, U.S. regulatory approvals with the FDA clearing devices like the Amplatzer PFO Occluder in October 2016 and the Gore Cardioform Septal Occluder in March 2018 have provided a clear regulatory pathway that supports broader adoption in structurally equipped cardiac centers nationwide.
China has become the biggest player in the Asia Pacific patent foramen ovale (PFO) closure devices market in 2026. China is emerging as the dominant country in the Asia Pacific Patent Foramen Ovale (PFO) Closure Devices Market due to its combination of high cardiovascular disease prevalence, rapid healthcare infrastructure expansion, increasing clinical awareness, and supportive regulatory environment. In 2026, the World Health Organization (WHO) reported that China accounts for over 40% of all strokes in the Asia Pacific, with roughly 2.5 million new ischemic strokes annually, many being cryptogenic and associated with PFO. Growing investment in tertiary hospitals and specialized cardiac centers in major urban regions such as Beijing, Shanghai, and Guangzhou has improved access to interventional cardiology and minimally invasive procedures. Clinical studies published in Frontiers in Cardiovascular Medicine, 2025 indicate that PFO closure adoption is increasing, supported by evidence showing a >90% procedural success rate with low complication risk. The China National Medical Products Administration (NMPA) has cleared multiple PFO occluder devices, aligning regulatory pathways with international standards, further driving adoption and making China the fastest-growing hub in the Asia Pacific PFO closure market.
Some of the major key players in patent foramen ovale (PFO) closure devices market is AGA Medical, Abbott (previously known as St Jude Medical, Inc.), WL Gore and Associates, Swissimplant AG, and Occlutech.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.6 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.6% | 2033 Value Projection: | USD 2.6 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AGA Medical, Abbott (previously known as St Jude Medical, Inc.), WL Gore and Associates, Swissimplant AG, and Occlutech |
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
